Search

50 patients with weeping dermatoses were treated with the investigational preparation SH K 183 MB - Nerisona Cream. Very good or good results were achieved in 90% of the cases. No systemic or topical side effects were observed. The cream was assessed as being very good in respect of its cosmetic properties.

Diflucortolone valerate 0.1% in the form of a cream - Nerisona Cream - was investigated in various dermatological diseases. Very good results were achieved in 68.7% of the total of 64 treated cases, good results in 18.8%, moderate results in 9.4% and poor results in 3.1% of the cases. The patients assessed the cosmetic properties of Nerisona Cream as excellent. No side effects were observed.

Diflucortolone valerate 0.1% (investigational number SH K 183 MB) in the form of a cream was clinically investigated in 41 patients with dermatological disorders. All the patients had been treated previously with other topical preparations, but without success. Complete healing or distinct improvement of the objective and subjective symptoms of the disorders was achieved in 100% of the cases treated with the investigational preparation. No side effects were observed at all.

The aim of the study was to compare the therapeutic effect of the new corticoid, diflucortolone valerate, with the effect of fluocinolone acetonide. The study was conducted as a randomised double-blind trial in 60 patients with various dermatoses. The results were good in 89% of the cases treated with diflucortolone valerate fatty ointment, while the same result was achieved in only 63.5% of the cases treated with fluocinolone acetonide ointment. No side effects were observed during the use of diflucortolone valerate fatty ointment, while local side effects occurred in 2 cases during the use of fluocinolone acetonide ointment.

The new corticosteroid diflucortolone valerate was clinically investigated in an international, multi-centre trial by a total of 162 dermatologists in 22 countries in more than 6,285 patients with inflammatory and allergic skin diseases. Depending on the condition of the skin, diflucortolone valerate was applied as a cream, ointment or fatty ointment at a concentration of 0.1%. Most of the patients treated with the cream displayed weeping skin conditions. The ointment was used mainly in patients with neither weeping nor very dry skin conditions, while the fatty ointment was employed mainly in very dry processes. After the exclusion of invalid record forms, 5,578 cases remained for computer evaluation. The results confirm that the success rate in local corticoid therapy can be improved by adapting the base to the respective skin condition. The forms investigated were found to be highly effective preparations with excellent skin tolerance. They can be placed on a par with today's leading topical corticoid preparations.

The investigational preparation Nerisona Cream (diflucortolone valerate 0.1%, investigational no. SH K 183 MB) was used in 47 patients with various inflammatory or pruriginous dermatoses. Either very good or good results were achieved in 89.3% of the cases. Nearly all the patients thought highly of the cosmetic properties of the preparation. No side effects were observed.

Diflucortolone valerate was clinically investigated as a fatty ointment in 30 dermatological patients. Although this form of application is a special presentation for the treatment of very dry dermatoses, patients with not so dry and weeping dermatoses were also treated in this trial, the object being to include the role played by the vehicle in the results of therapy. Very good to good results were achieved in 80% of the cases treated, while the result was observed to be poor in only 10% of the cases. This latter percentage is comprised for the greater part of patients who had previously been treated with other corticoids and of patients with weeping dermatoses.

Diflucortolone valerate 0.1% in cream form was investigated in 50 patients with various inflammatory dermatoses. The results were very good in 82% of the cases, good in 8% and moderate in 10%.

The clinical efficacy of diflucortolone valerate as a fatty ointment was investigated in 65 patients with very dry dermatoses. The results were very positive, being excellent in atopic eczema, neurodermatitis and atopic cheilitis. No side effects were observed.

The authors investigated the therapeutic effect of diflucortolone valerate as an ointment in 40 patients with inflammatory dermatoses of various etiology. They described the antiphlogistic and antipruritic effect of the preparation as excellent and practically devoid of any side effects and cosmetic problems.

59 patients with various skin disorders - most of them in the acute stage - were treated in this trial. The topical investigational preparation was a cream containing 0.1% diflucortolone valerate. The results confirmed that the preparation has a quick-acting and effective antipruritic and antiphlogistic action. The results achieved were good or very good in 91.52% of cases and moderate in 8.47%. No side effects were observed.

Diflucortolone valerate 0.1% (Nerisona), a new topical corticoid, was clinically investigated in ointment form in 51 patients suffering from neither weeping nor very dry allergic and inflammatory skin diseases. The results obtained were good, improvement being observed in 92.1% of the treated cases. The cosmetic properties of the preparation were excellent. No local or systemic side effects were observed.